Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature

• Main Authors: Yassir Sbitti, Hafsa Chahdi, Khaoula Slimani, Adil Debbagh, Anouar Mokhlis, Abderrahmane Albouzidi, Fahd Bennani, Hassan Errihani, Mohamed Ichou
• Format: Article
• Language: English
• Published: BMC 2017-07-01
• Series: Journal of Medical Case Reports
• Subjects: Pemetrexed; Renal damage; Non-small cell lung carcinoma
• Online Access: http://link.springer.com/article/10.1186/s13256-017-1348-6

Abstract Background Pemetrexed maintenance therapy holds tremendous potential in improving the survival of patients with advanced pulmonary adenocarcinoma. Major side effects include myelosuppression and cutaneous reactions. However, little data are available on pemetrexed nephrotoxicity. Our case describes clinically relevant renal events leading to treatment discontinuation in routine practice. Case presentation We report a case of a 69-year-old Moroccan man treated for metastatic non-small cell lung cancer. He was not on any other medications and he did not receive any nephrotoxic agents. He was exposed to intravenously administered contrast from thoracoabdominal computed tomography in the week of his last pemetrexed treatment. He developed kidney disease related to pemetrexed. He was submitted to renal biopsy, which showed acute tubular damage and interstitial fibrosis. His kidney function remained impaired, but stable, after discontinuation of pemetrexed therapy. He died 5 months later. Conclusions Medical oncologists should be aware of renal adverse events for patients with advanced non-small cell lung cancer eligible for pemetrexed maintenance therapy. Suggestions for mitigating the risk for renal toxicities (dehydration, non-steroidal anti-inflammatory drugs and zoledronic acid, radiocontrast agents) during pemetrexed maintenance should be followed to enable early detection and management of this adverse event.